AUBAGIO (teriflunomide) oral tablet

Transcription

1 AUBAGIO (teriflunomide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Pharmacy Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines. The section identified as Description defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage. The section identified as Criteria defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational. State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity. Pharmacy Coverage Guidelines are subject to change as new information becomes available. For purposes of this Pharmacy Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable. BLUE CROSS, BLUE SHIELD and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ. Description: Aubagio (teriflunomide) is a pyrimidine synthesis inhibitor indicated for the treatment of individuals with relapsing forms of multiple sclerosis (MS). It is the principle active metabolite of Leflunomide. Teriflunomide is an immunomodulatory agent with anti-inflammatory properties. It inhibits the mitochondrial enzyme involved in pyrimidine synthesis, dihydro-orotate dehydrogenase. The exact mechanism by which Teriflunomide exerts its therapeutic effect in MS is unknown. It is thought that Teriflunomide helps reduce the number of active T and B lymphocytes, two types of WBCs, thought to be particularly damaging in MS. MS is a chronic autoimmune disorder of the central nervous system (CNS) in which white blood cells (WBCs) attack and damage the myelin sheath of nerve cells in the CNS. This damage disrupts transmission of nerve impulses. Damage occurs in areas of the brain, spinal cord, and optic nerves. The damage ultimately leads to progressive physical and cognitive disabilities. The clinical course of MS is highly variable. There are four recognized clinical forms: relapsing remitting (RRMS), secondary progressive (SPMS), primary progressive (PPMS), and progressive relapsing (PRMS). RRMS is the most common form of the disease. Page 1 of 9

2 Because MS can affect any area of the brain, optic nerve, or spinal cord, MS can cause almost any neurologic symptom. Patients often present as young adults with 2 or more clinically distinct episodes of CNS dysfunction with at least partial resolution. Episodes involve numbness, weakness, or incoordination affecting an arm, a leg, or both. Additional symptoms include pain, vertigo, cognitive deficits (such as impaired memory, attention, or judgment), fatigue, speech deficits (such as dysarthria or less commonly aphasia), and bowel, bladder, and sexual dysfunction. The pathological hallmark of MS is the cerebral or spinal plaque on magnetic resonance imaging (MRI). Plaques are discrete regions of demyelination with relative preservation of axons. The neurologic history and physical examination help establish the diagnosis of MS. Diagnostic criteria are symptoms and signs disseminated in time and space (i.e., more than one episode involving more than one area of the CNS). These criteria have been largely replaced by the McDonald criteria, developed in 2001 by the International Panel on the Diagnosis of Multiple Sclerosis. The McDonald criteria retain many features of the original criteria and are intended for use in both clinical practice and clinical trial settings. Diagnoses of definite MS, possible MS, or, if there is a better explanation for the clinical presentation, not MS are determined by findings on clinical exam, MRI, cerebrospinal fluid, and visual evoked potentials. The term clinically isolated syndrome (CIS) describes patients who have suffered a first clinical attack but do not meet diagnostic criteria for definite MS. The most recent update in 2010 allows the diagnosis of MS in some patients with CIS. Definitions: Forms of multiple sclerosis: Relapsing-remitting multiple sclerosis (RRMS) This form of MS is characterized by acute relapses that are followed by some degree of recovery; patients do not develop worsening of disability between relapses. Secondary progressive multiple sclerosis (SPMS) This form of MS is defined as sustained progression of physical disability occurring separately from relapses, in patients who previously had RRMS. There may, or may not be intermittent relapses, remissions, or periods of temporary minor improvements. As long as the person continues to have relapses, the SPMS course is considered to be both progressive and relapsing. Progressive-relapsing multiple sclerosis (PRMS) This form of MS is characterized by steadily worsening disease from the beginning, but with occasional relapses along the way. PRMS is considered to be both a progressive and a relapsing form of the disease because people experience steady disease progression and relapses. Primary-progressive multiple sclerosis (PPMS) This form of MS is defined as progression of disability from onset without superimposed relapses. This type of MS is characterized by a steady decline in function from the beginning without acute attacks. There are no distinct relapses or remissions. This is not a relapsing form of MS. Page 2 of 9

4 Drug related events: Ineffective / failure Use of a drug employing optimal doses (FDA-recommended doses) for optimal duration; where the condition being treated has not improved or worsened A request for branded agent due to generic drug failure or ineffectiveness will be assessed for potential approval with documentation of use of optimal dose / duration of the generic product and meeting other criteria within the coverage guideline. When the drug in question is a combination product, there must be documentation of failure / ineffectiveness of concurrent use (each ingredient used at the same time) of individual generic components. When the drug in question is a low dose formulation, there must be documentation of failure / ineffectiveness of low dose generic formulation. Adverse Drug Event: Allergic reaction / Hypersensitivity / Intolerance Use of a drug produced a significant reaction where continued use of the drug places the individual at risk for either lack of improvement or worsening of the condition being treated or at risk for harm and the concern is documented in medical record. A significant adverse drug event is when an individual s outcome is death, life-threatening, hospitalization (initial or prolonged), disability resulting in a significant, persistent, or permanent change, impairment, damage or disruption in the individuals body function/structure, physical activities or quality of life, or requires intervention to prevent permanent impairment or damage. Allergic reaction / hypersensitivity may or may not involve the active ingredient. When the active ingredient is involved, use of same or a chemically similar agent places the individual at risk for harm when the same or chemically similar agent is used. The subsequent reaction may be the same as the original reaction or a more exaggerated response may be seen, potentially placing the individual at even greater risk for harm. If the reaction occurred from the active/main generic ingredient; request for branded agent with same active ingredient will not be considered unless it is proven (documented) that active ingredient did not cause reaction and the request meets other criteria within the coverage guideline Intolerance these events represent circumstance(s) where use of a drug produced a significant reaction and continued use may result in non-adherence to proposed therapy and this concern is documented in medical record Contraindication Use of a drug that is not recommended by the manufacturer or FDA labelling Use of any drug in the face of a contraindication is outside of the FDA and manufacturer s labelled recommendation and is considered investigational or experimental Non-adherence Individual does not follow prescribe regimen that places the individual at risk for lack of improvement or worsening of the condition being treated and this concern is documented in medical record Page 4 of 9

5 Precertification: Precertification (Prior Authorization) is required for members with a Blue Cross Blue Shield of Arizona (BCBSAZ) pharmacy benefit for medication(s) or product(s) indicated in this guideline. This Pharmacy Coverage Guideline does not apply to FEP or other states Blues Plans. Information about medications that require precertification is available at Some large (100+) benefit plan groups may customize certain benefits, including adding or deleting precertification requirements. All applicable benefit plan provisions apply, e.g., waiting periods, limitations, exclusions, waivers and benefit maximums. Criteria: See Resources section for FDA-approved dosage. Precertification for Aubagio requires completion of the specific request form in its entirety. All requested data must be provided. Once completed the form must be signed by the prescribing provider and faxed back to BCBSAZ Pharmacy Management at (602) or to Incomplete forms will be returned. FDA-approved dosage of Aubagio is considered medically necessary treatment of relapsing forms of Multiple Sclerosis when ALL of the following criteria are met: 1. Individual is 18 years of age and older 2. Medical record documentation of a confirmed diagnosis of ONE of the following forms of relapsing Multiple Sclerosis Relapsing-remitting multiple sclerosis (RRMS) Secondary progressive multiple sclerosis (SPMS) Progressive-relapsing multiple sclerosis (PRMS) A first clinical episode that has magnetic resonance imaging (MRI) features that are consistent with multiple sclerosis 3. ALL of the following baseline tests have been completed before initiation of treatment: Negative pregnancy test in a woman of child bearing potential A recent (within last 6 months) alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin A recent (within last 6 months) complete blood count (CBC); infection must be resolved prior to initiation Screening for latent tuberculosis; with latent infection treatment initiated prior to initiation Blood pressure is measured; with elevated blood pressure managed during treatment Page 5 of 9

6 4. Absence of ALL of the following contraindications: Pregnancy in a woman who is of child bearing potential Severe hepatic impairment (Child-Pugh Class C) Concurrent use with Leflunomide 5. Absence of ALL of the following exclusions: Use of inadequate contraception in both woman and men Woman who is breast feeding an infant or child Acute liver disease Concurrent use with cholestyramine Concurrent use with activated charcoal use Active acute or chronic infection unless the infection is resolved prior to initiation Severe immunodeficiency, bone marrow disease, or severe, uncontrolled infection Immunizations with live vaccines updated prior to initiation Aubagio for all other indications not previously listed or if above criteria not met is considered experimental or investigational based upon: 1. Lack of final approval from the Food and Drug Administration, and 2. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes, and 3. Insufficient evidence to support improvement of the net health outcome, and 4. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives, and 5. Insufficient evidence to support improvement outside the investigational setting. This includes but is not limited to: Primary-progressive multiple sclerosis (PPMS) Clinically isolated syndrome (CIS) with a MRI without lesions suggestive of MS Neuromyelitis optica (NMO) and NMO spectrum disorder Acute disseminated encephalomyelitis (ADEM) Optic neuritis Transverse myelitis Brainstem syndrome Combination with other disease modifying MS therapy History: Date: Activity: Pharmacy and Therapeutics review Approved Director Pharmacy Mgmt. review Reorganized & added to Description section, added to Definitions section the McDonald criteria, added item to Criteria #2, split Criteria #3 into three separate criteria, added item to new Criteria #3 and to new Criteria # 5 Pharmacy and Therapeutics review Approved Annual Review Re-titled Criteria 2 and 3 (see below), added to Page 6 of 9

7 experimental or investigational uses and revised description of Clinical isolated syndrome, added to Resources Pharmacy and Therapeutics review Adopted guideline Director Pharmacy Mgmt. review Review Criteria Revisions: Date: Criteria: Revisions: Medical record documentation of a confirmed diagnosis of ONE of the following forms of relapsing Multiple Sclerosis Relapsing-remitting multiple sclerosis (RRMS) Secondary progressive multiple sclerosis (SPMS) Progressive-relapsing multiple sclerosis (PRMS) Documentation the following conditions and/or circumstances have been ruled out and/or assessed: Severe hepatic impairment (Child-Pugh Class C) Pregnancy or likely to become pregnant due to lack of adequate contraception Breast feeding an infant or child Concurrent Leflunomide use Concurrent Cholestyramine use Concurrent Activated charcoal use Pre-existing acute or chronic liver disease prior to initiation of Aubagio using a recent (within last 6 months) serum transaminase and bilirubin Active or chronic infection prior to initiation of Aubagio using a recent (within last 6 months) Complete Blood Count; infection must be resolved prior to Aubagio use Tuberculosis, screened before treatment; with latent infection treatment initiated prior to Aubagio use Medical record documentation of a confirmed diagnosis of ONE of the following forms of relapsing Multiple Sclerosis Relapsing-remitting multiple sclerosis (RRMS) Secondary progressive multiple sclerosis (SPMS) Progressive-relapsing multiple sclerosis (PRMS) A first clinical episode that has magnetic resonance imaging (MRI) features that are consistent with multiple sclerosis 3. ALL of the following baseline tests have been completed before initiation of treatment: Negative pregnancy test in a woman of child bearing potential A recent (within last 6 months) alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin A recent (within last 6 months) complete blood count (CBC); infection must be resolved prior to initiation Screening for latent tuberculosis; with latent infection treatment initiated prior to initiation Blood pressure is measured; with elevated blood pressure managed during treatment 4. Absence of ALL of the following contraindications: Pregnancy in a woman who is of child bearing potential Severe hepatic impairment (Child-Pugh Class C) Concurrent use with Leflunomide Page 7 of 9

8 Immunizations with live vaccines updated prior to initiation of Aubagio use Inadequate contraceptive use for both men on Aubagio and their female partner Documentation of ONE of the following forms of relapsing Multiple Sclerosis Documentation the following conditions and/or circumstances HAVE BEEN RULED OUT Experimental or Investigational uses: Added items and revised Clinically isolated syndrome (CIS) 5. Absence of ALL of the following exclusions: Use of inadequate contraception in both woman and men Woman who is breast feeding an infant or child Acute liver disease Concurrent use with cholestyramine Concurrent use with activated charcoal use Active acute or chronic infection unless the infection is resolved prior to initiation Severe immunodeficiency, bone marrow disease, or severe, uncontrolled infection Immunizations with live vaccines updated prior to initiation 2. Medical record documentation of a confirmed diagnosis of ONE of the following forms of relapsing Multiple Sclerosis 3. Documentation the following conditions and/or circumstances have been ruled out and/or assessed: Added: Neuromyelitis optica (NMO) and NMO spectrum disorder, Acute disseminated encephalomyelitis (ADEM), Optic neuritis, Transverse myelitis, Brainstem syndrome, Combination MS therapy Revised: Clinically isolated syndrome (CIS) with a MRI without lesions suggestive of MS Resources: Refer to package insert for complete dosing information. FDA-approved indication and dosage: Page 8 of 9

9 Indication AUBAGIO is indicated for the treatment of patients with relapsing forms of Multiple Sclerosis Safety and effectiveness in pediatric patients have not been established It is contraindicated in: Severe hepatic impairment Pregnancy or women of childbearing potential not using reliable contraception Concurrent Leflunomide use Recommended Dose The recommended dose is 7 mg or 14 mg once daily with or without food If needed, accelerated elimination may be accomplished by use of either: o Cholestyramine 8 g orally every 8 hours for 11 days If the 8 g dose is not tolerated, may use 4 g orally every 8 hours o Activated charcoal 50 g orally every 12 hours for 11 days If either regimen is not tolerated, treatment days do not need to be consecutive unless rapid elimination is truly needed Aubagio. Package Insert. Revised by manufacturer a and reviewed on Aubagio. Package Insert. Revised by manufacturer and reviewed on November 26, 2012 BlueCrossBlueShield Association Technology Evaluation Center Specialty Pharmacy Report # : Teriflunomide Polman CH, Reingold SC, Banwell B, et al.: Diagnostic Criteria for Multiple Sclerosis: 2010 Revisions to the McDonald Criteria. Annals of Neurology 2011;69: Rio J, Comabella M, Montalban X: Multiple sclerosis: Current treatment algorithms. Curr Opin Neurol 2011;24: Page 9 of 9

CNS DEMYLINATING DISORDERS Multiple sclerosis A Dutch saint named Lidwina, who died in 1433, may have been one of the first known MS patients. After she fell while ice skating, she developed symptoms such

The Nuts and Bolts of Multiple Sclerosis Rebecca Milholland, M.D., Ph.D. Center for Neurosciences Objectives Discuss which patients are at risk for Multiple Sclerosis Discuss the diagnostic criteria for

OHTAC Recommendation Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency Presented to the Ontario Health Technology Advisory Committee in May 2010 May 2010 Issue Background A review on the

AVONEX/BETASERON/COPAXONE/EXTAVIA/GILENYA/REBIF/TYSABRI Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 5 PATIENT INFMATION Surname First Name Middle Initial Sex Date

What is Multiple Sclerosis? Gener al information Kim, diagnosed in 1986 What is MS? Multiple sclerosis (or MS) is a chronic, often disabling disease that attacks the central nervous system (brain and spinal

Teriflunomide (Aubagio) 14mg once daily tablet Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Teriflunomide. The decision

Disease Modifying Therapies for MS The term disease-modifying therapy means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Chemotherapy The literal meaning of the term chemotherapy is to treat with a chemical agent, but the term generally refers

History & Discovery 54 2 History & Discovery 2.1 Who first described NMO? 2.2 What is the difference between NMO and Multiple Sclerosis? 2.3 How common is NMO? 2.4 Who is affected by NMO? 2.1 Who first

Understanding Multiple Sclerosis Tim, diagnosed in 2004. What Is Multiple Sclerosis? Multiple sclerosis (MS) is a neurologic disorder that affects the central nervous system (CNS). The CNS includes the

Trauma Insurance Claims Seminar Invitation Introduction Since the development of Trauma Insurance in Australia in the 1980s, the product has evolved at a great pace. Some of the challenges faced by claims

Chapter 2 Clinical features Clinical manifestations The wide range of symptoms and signs of multiple sclerosis (MS) reflect multifocal lesions in the central nervous system (CNS), including in the afferent

Supporting MS-Related Disability Claims to Private Insurers: The Physician s Role What Is This Guide? This guide was compiled by the National Multiple Sclerosis Society as an aid to health care professionals

MS Priority Setting Partnership Voting for your top research questions Survey Prioritising important research questions for multiple sclerosis a partnership between people affected by MS and healthcare

FOR MS RELAPSES Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU As a person with multiple sclerosis (MS), you know firsthand the profound impact MS relapses can have on your

Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have

FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to

TITLE: Treatment of Patients with Multiple Sclerosis: A Review of Guidelines DATE: 13 March 2013 CONTEXT AND POLICY ISSUES Multiple sclerosis (MS) is an unpredictable, often disabling disease of the central

Conflict of Interest Declaration Overview of New Medications for Multiple Sclerosis I or my spouse have no actual or potential conflict of interest in relation to this activity. Crystal Obering, Pharm.D.,

What is MS? 1 Neuron Damaged myelin due to inflammation MS is a chronic immunemediated disease that affects the central nervous system (CNS) Is a disease that affects both white and gray matter Interrupted

0 A Letter From the MS Coalition The treatment of multiple sclerosis (MS) requires a comprehensive management strategy. One important component of that strategy is modifying the disease course. When deciding

Disease Modifying Therapies for MS The term disease-modifying therapy (DMT) means a drug that can modify or change the course of a disease. In other words a DMT should be able to reduce the number of attacks

Choices Disease Modifying Treatments Disease modifying treatments (DMTs) are medications which modify the disease course. They target inflammation and are designed to reduce the damage caused by relapses.

Optic Neuritis Your doctor thinks that you have had an episode of optic neuritis. This is the most common cause of sudden visual loss in a young patient. It is often associated with discomfort in or around

An introduction to Relapsing remitting MS What does it mean when you are diagnosed with relapsing remitting MS? There are three main types of MS: relapsing remitting MS, primary progressive MS and secondary

ABN Guidelines for 2007 Treatment of Multiple Sclerosis with ß-interferon and Glatiramer Acetate Published by the Association of British Neurologists Ormond House, 27 Boswell Street, London WC1N 3JZ Contents

June 2013 Guide to Important Safety Information Using GILENYA In Patients with Relapsing Forms of Multiple Sclerosis R GILENYA (fingolimod) is a sphingosine 1-phosphate receptor (S1P) modulator indicated

ETMIS 2012; Vol. 8: N o 7 Summary Diagnosis and Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in People with Multiple Sclerosis (MS) March 2012 A production of the Institut national d

An introduction to multiple sclerosis for people who have recently been diagnosed When you have just been diagnosed with multiple sclerosis, you will probably have many questions about the condition and

A guide to the accelerated elimination procedure Prescribing information and information on adverse event reporting can be found on the last page. What is the accelerated elimination procedure? An accelerated

Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website. It is provided for patients and healthcare professionals to increase the transparency of

IF YOU ARE RECEIVING (NATALIZUMAB) TREATMENT WITH TYSABRI FOR RELAPSING-REMITTING MS Read the patient information leaflet that accompanies the medicine carefully. 1 This brochure is a supplement to the

NEW DIRECTION IN THE IMPROVEMENT OF CLINICAL CONDITIONS IN MULTIPLE SCLEROSIS PATIENTS By F. De Silvestri, E. Romani, A. Grasso Introduction Multiple sclerosis (MS), in its many and varied clinical forms,

BETAFERON is a Prescription Medicine. Use strictly as directed. Consult your pharmacist or other health professional in case of side effects. BETAFERON is reimbursed for some patients. See your neurologist

Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an

Gilenya Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Gilenya. The decision to start this form of treatment can be difficult.

Teriflunomide (Aubagio) Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 We hope you find the information in this factsheet helpful. If you would like to speak

Summary Multiple Sclerosis (MS) is a chronic disease of the brain and the spinal cord. The cause of MS is unknown. MS usually starts in young adulthood. In the course of the disease progression of neurological

Page: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted

Transverse Myelitis ISBN 978-1-901893-57-1 A guide for patients and carers The Brain and Spine Foundation provides support and information on all aspects of neurological conditions. Our publications are

MULTIPLE SCLEROSIS 2015 Mercedes P Jacobson, MD, Department of Neurology Temple University School of Medicine Disclosure Research support, Sunovion and Marinus for epilepsy research Goals and Objectives

Specialist Working Group for Neurology Proposed changes to the Criteria for the clinical use of intravenous immunoglobulin in Australia, Second Edition ITEM Condition Name Multiple Sclerosis (MS) Multiple

April 2013 Experts at your fingertips call now CBT IN THE CITY Check out our new services in you local area contents. A message from Susie, Information Multiple Sclerosis CBT can make a difference on the

Multiple Sclerosis & MS Ireland Media Fact Sheet This fact sheets gives a summary of the main facts and issues relating to Multiple Sclerosis and gives an overview of the services offered by MS Ireland.